A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer

Clin Prostate Cancer. 2004 Mar;2(4):241-3. doi: 10.3816/cgc.2004.n.006.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I

MeSH terms

  • Administration, Oral
  • Humans
  • Lenalidomide
  • Male
  • Neoplasm Metastasis
  • Palliative Care
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / pathology
  • Research Design
  • Thalidomide / administration & dosage
  • Thalidomide / analogs & derivatives*
  • Thalidomide / therapeutic use*

Substances

  • Thalidomide
  • Lenalidomide